Jared Whitlock retweeted
Radical Numerics—the startup entangled in controversy over its AI-generated phage work—has developed a model to identify AI-engineered pathogens without an internet connection. My story for @WIRED: wired.com/story/startup-figh…
Jared Whitlock retweeted
“It’s very clear Epic owns the market. Its prices are extraordinary. It has killed innovators left and right — it’s time for a change.” A must-read story from Casey Ross and @brittanytrang, who are investigating the electronic health records giant Epic. statnews.com/2026/10/28/epic…
Jared Whitlock retweeted
A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public. An exclusive by @bborrell from us and @ScienceMagazine.
science.org/content/article/…
Jared Whitlock retweeted
Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood
statnews.com/2026/04/30/crai… via @statnews
Jared Whitlock retweeted
I'm sad to learn that J. Craig Venter, a key figure in modern genomics and an inveterate troublemaker, passed away.
Craig was very important to the study of human genetics and the biotechnology industry. He also had an impact on my career. The pitch that led @michaelnoer to hire me at Forbes in 2000 was about Venter's company, Celera Genomics, and its work on the mouse genome.
Seventeen years, later, Michael edited a cover story I wrote about Venter for Forbes.
Jared Whitlock retweeted
Must read story from @antonioregalado about a biotech that wants to make brainless clones as a personal source of organ donation or even body transplant. They pitched themselves to me as an alternative to animal models company. That wasn't the full story. technologyreview.com/2026/03…
Jared Whitlock retweeted
Theia Group set out to revolutionize space-based surveillance. Its enigmatic founder, a former NASA engineer, envisioned nothing less then "Google for the physical world," he told me from jail.
My @BW investigation into Theia's dramatic rise & fall:
bloomberg.com/news/features/…
Jared Whitlock retweeted
China competition is coming for the US's multimillion-dollar gene therapies -- a must-read from @Jared_Whitlock about what's happening there and how it will affect access around the world:
endpoints.news/china-is-taki…
Jared Whitlock retweeted
Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock
endpoints.news/everyone-medi…
Jared Whitlock retweeted
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
endpoints.news/everyone-medi…
Jared Whitlock retweeted
Hey everyone! I'm starting a monthly newsletter on @Substack of curated longform journalism recommendations. I'll be highlighting the stories that've stuck with me the most each month + two books & a podcast. 1st post here. Please subscribe and share! open.substack.com/pub/thelon…
Jared Whitlock retweeted
Honored to have won a George Polk award for my coverage of the turmoil at FDA last year. The STAT team was also recognized for reporting on the Trump admin's impact on health and science. statnews.com/2026/02/18/stat…
Jared Whitlock retweeted
With a valuation of about $61 billion, Hengrui is now larger than Takeda and Bayer.
But there’s still one big item on its bucket list: selling its own treatments outside of China. My story in @endpts:
endpoints.news/hengrui-blaze…
Jared Whitlock retweeted
At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development. endpoints.news/jpm26-drugmak…
Jared Whitlock retweeted
You know the China biotech story is here to stay when Endpoints starts hiring in Hong Kong. Exciting opportunity!
📢Some BIG news here at Endpoints: We're building in China. This year, we'll be hiring a senior journalist in Hong Kong who can lead on our coverage of China biotech.
This is one of biotech's most important stories. Want to shape it? DM me, or apply.
ats.rippling.com/endpointsne…
Jared Whitlock retweeted
Pre-JPM news flow update: The embargoes are so plentiful that our copy editor is drawing filed stories from a hat.
Jared Whitlock retweeted
📢Some BIG news here at Endpoints: We're building in China. This year, we'll be hiring a senior journalist in Hong Kong who can lead on our coverage of China biotech.
This is one of biotech's most important stories. Want to shape it? DM me, or apply.
ats.rippling.com/endpointsne…
Jared Whitlock retweeted
The gene editing toolbox has exploded since CRISPR was invented, with each new tool promising to be better than the last.
Read my third deep and final deep dive of 2025 on the #CRISPR gene editing field's growing pains in Endpoints News: @endpts
endpoints.news/as-gene-editi…
Jared Whitlock retweeted
Amazing journey for Maxwell Freed...
See my post from back in 2019... they raised the money to fund a gene therapy, followed a saga thru academia and Taysha... and, despite all that, now Maxwell has been dosed and appears to be responding...
Motivated, passionate parents are a force in bringing new therapies forward...
endpoints.news/nationwide-ch…
My friend Amber Freed's son Maxwell has a rare SLC6A2 mutation, linked to severe epilepsy.
If you have 6 min, watch her quest to fund a gene therapy for Max: facebook.com/690805510/posts…. @SLC6A1_Mom
Be thankful & wake up every day trying to work on things that make a difference
Jared Whitlock retweeted
FDA says it won't release details of claimed Covid vaccine deaths in 'near term' - endpoints.news/fda-says-it-w…



















